Iloprost

Iloprost, the active ingredient in Iloprost, is a prostacyclin analog presented as an intravenous solution for intravenous use. It is indicated for the management of pulmonary arterial hypertension and for the treatment of digital ulcers associated with systemic sclerosis in adult patients.

GNH USA supplies Iloprost as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, adhering to EU quality standards.

Iloprost is a prostacyclin analog used in the pulmonary vascular disease pathway.

Pulmonary arterial hypertension: improves exercise capacity and delays disease progression through pulmonary vasodilation. Digital ulcers associated with systemic sclerosis: promotes ulcer healing and reduces new ulcer formation by enhancing microcirculatory flow.

Common Side Effects: - Headache: mild to moderate intensity during infusion. - Flushing: transient warmth and redness of the skin. - Nausea: occasional gastrointestinal upset. - Jaw pain: discomfort during chewing. - Hypotension: drop in blood pressure, especially with rapid infusion. - Infusion site pain: local discomfort at the catheter site.

Serious or Rare Side Effects: - Pulmonary edema: accumulation of fluid in the lungs. - Severe hypotension: marked blood pressure reduction requiring intervention. - Bleeding: increased risk due to antiplatelet effect. - Thrombocytopenia: low platelet count. - Arrhythmia: abnormal heart rhythm.

Iloprost requires careful monitoring due to its potent vasodilatory effects.

Pregnancy: safety not established; avoid unless benefit outweighs risk. Renal impairment: monitor renal function and adjust infusion rate if needed. Hepatic impairment: use with caution; liver dysfunction may alter drug clearance. Concomitant vasodilators: risk of additive hypotension; adjust dosing accordingly. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Iloprost may interact with several cardiovascular and anticoagulant agents.

Major Interactions (Avoid): - Epoprostenol: additive vasodilation may cause severe hypotension. - Sildenafil: combined use can lead to profound blood pressure drops. - Warfarin: enhanced antiplatelet effect increases bleeding risk.

Moderate Interactions (Monitor Closely): - Calcium channel blockers: monitor blood pressure for additive effects. - Beta‑blockers: may blunt desired vasodilatory response. - Heparin or other anticoagulants: observe for signs of excessive bleeding.